ClinicalTrials.gg
CompletedNCT03268096DB-SEP15Updated Apr 22, 2022

Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination

An observational study in Multiple Sclerosis, Pathologic Processes and Tomography, Optical Coherence, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2022-04-22.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
182
Sex
All
01

Study summary

Knowledge of the evolution of multiple sclerosis (MS) and its long-term prognostic factors is essential to guide the therapeutic management. However, it remains partial and concerns above all data collected during the first years of the disease. The evolution towards disability can only be assessed after a follow-up of more than 10 years and does not depend solely on the initial inflammatory activity of the disease. We propose to realize a standardized clinical assessment, an optical coherence tomography (OCT) and a cerebral MRI 15 years after the first clinical manifestation of the disease.

Clinical and paraclinical assessment will consist in the realization of additional MRI sequences in order to obtain more precise information on cerebral lesions (unconventional parameters). Optical coherence tomography (new generation device) will also be performed on both eyes to describe the thickness of the different layers of the retina. A clinical evaluation will be performed with the Expanded Disability Status Scale (EDSS).

This study aims:

  1. to describe the current clinical situation of patients (e.g. percentage of patients with moderate or severe disability)
  2. to explore the associations between MRI parameters, those measured with OCT and clinical characteristics (disability)
  3. to explore clinical and paraclinical prognostic factors of pejorative evolution (disability, severe cerebral atrophy, etc.)
02

Conditions studied

  • Multiple Sclerosis
  • Pathologic Processes
  • Tomography, Optical Coherence
  • Magnetic Resonance Imaging
  • Prognosis
03

In context

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

This study's enrollment of 182 is above the median of 100 across 970 observational studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who had an episode of demyelination at least 10 years ago

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First episode of demyelination occurred at least 10 years ago
  • Hospitalized in the neurology department during this episode
  • Insured with a social security scheme
  • Having given his consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • to 3 Tesla MRI and injection of contrast media
  • Benefiting from a legal protection measure
  • Pregnant or nursing mother
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
182 participants (actual)
Patient registry
No

Interventions

  • DeviceCerebral MRI and Optical Coherence Tomography

    Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.

06

What researchers measure

Primary outcomes

  1. Disability assessed with EDSS (Expanded Disability Status Scale)

    Disability assessment will be carried out using the EDS (Expanded Disability Status) Scale. This scale ranges from 0 to 10. Binary or ordered variables will be considered with various thresholds (for example, a score equal to 3 corresponds to moderate disorders ; a score equal to 6 corresponds to major disorders (need of a stick to walk 100 meters)).

    Time frame: Baseline

07

Study locations

1 site
  • Fondation Ophtalmologique A. de Rothschild
    Paris, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Nov 2021, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2017
First posted
Aug 31, 2017
StartActual
May 3, 2017
Primary completionActual
Nov 3, 2021
CompletionActual
Nov 3, 2021
Last update
Apr 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03268096
Responsible party
Sponsor
First posted
Aug 31, 2017
Start date
May 3, 2017
Primary completion
Nov 3, 2021
Completion
Nov 3, 2021
Last update
Apr 22, 2022

Study contacts

Antoine Guéguen, MD
principal investigator · Fondation Ophtalmologique A. de Rothschild

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion